Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Merus N.V. logo — Oncology company developing Biclonics® bispecific antibody t...

Merus N.V.

Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c

Founded 2003 The Netherlands The Netherlands 185 employees Post-IPO Equity Total: $1.04B Biotechnology, Health Care +1

General Information

Company Name Merus N.V.
Founded Year 2003
Location The Netherlands The Netherlands
Founders / Decision Makers
Team member Team member
Employees 185
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Business Model B2B, Platform, B2B2B
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Merus N.V.. To contact Merus N.V., visit merus.nl.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Merus N.V. compare?

A PDF of Merus N.V. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Merus N.V. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Merus N.V.

Merus N.V., a biotechnology firm founded in 2003, is headquartered in The Netherlands. The company is at the forefront of developing innovative oncology solutions using its proprietary Biclonics® bispecific antibody therapeutics. This pioneering approach enables simultaneous multi-targeted tumor attacks, enhancing the immune response and inhibiting tumor growth pathways.

With over a decade of research and development, Merus N.V. has several promising drug candidates currently in clinical trials. The firm's commitment to revolutionizing cancer treatment is underscored by its strategic international partnerships and presence in both European and US markets. Additionally, its NASDAQ listing since 2016 highlights its financial standing and industry credibility.

Recently, the company secured a substantial $400.20M Post-IPO Equity investment, reflecting strong investor confidence and positioning Merus N.V. for continued growth in the Biotechnology and Health Care sectors. This funding is poised to advance their mission of developing best-in-class cancer therapeutics.

Business keywords: Biclonics®, bispecific antibody therapeutics, antibody-based biopharmaceuticals, Oligoclonics technology, immuno-oncology, cancer treatment, antibody engineering, tumor cell inhibition, immune system activation, biomarker development, clinical trials, oncology research, therapeutic antibodies, antibody discovery, cell biology

Services & Products

Development of Cancer Treatments
Clinical Trials Management
Research and Development in Biotechnology
Multiclonics Therapeutics

Target Customers

Cancer Patients Healthcare Providers Medical Researchers Pharmaceutical Industry

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $400.20M -
29 May 2024
Post IPO Equity $150.00M -
09 Aug 2023
Post IPO Equity $110.00M -
04 Nov 2021
Post IPO Equity $120.00M -
21 Jan 2021
Post IPO Equity $55.80M 3
Sofinnova Investments
Sofinnova Investments, EQT Life Sciences +1
14 Feb 2018
Post IPO Equity $80.00M -
23 Jan 2017
Grant €1.50M -
09 Nov 2016
Series C €72.80M 10
Novo Holdings Novartis Venture Fund RA Capital Management
Novo Holdings, Novartis Venture Fund +8
26 Apr 2015
Series B €31.00M 5
Novartis Venture Fund Bay City Capital Johnson & Johnson Development Corporation
Novartis Venture Fund, Bay City Capital +3
03 Oct 2013
Series B €21.70M 5
Novartis Venture Fund Aglaia Biomedical Ventures Bay City Capital
Novartis Venture Fund, Aglaia Biomedical Ventures +3
29 Jan 2010

View All 11 Funding Rounds

Merus N.V. Alternatives & Competitors

View All Alternatives
Merus N.V. vs
OncoResponse
OncoResponse United States

Interrogating for Cures

10 employees
Biopharma, Biotechnology
Compare Merus N.V. vs OncoResponse
Merus N.V. vs
2seventy bio
2seventy bio United States

It’s about time we think smarter and faster than cancer.

Acquired
122 employees
Biotechnology, Health Care
Compare Merus N.V. vs 2seventy bio
Merus N.V. vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
Also compare with: Merus N.V. vs Immunitas Therapeutics Immunitas Therapeutics Merus N.V. vs Microbiotica Microbiotica View all alternatives

FAQ About Merus N.V.

Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c
Merus N.V. was founded in 2003.
Merus N.V. is headquartered in The Netherlands.
Merus N.V. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Biclonics®, bispecific antibody therapeutics, antibody-based biopharmaceuticals and Oligoclonics technology. Its customers include Cancer Patients, Healthcare Providers and Medical Researchers.
Merus N.V. has a B2B, Platform and B2B2B business model. Its revenue comes from Product Sales, Licensing and Performance Based.
Merus N.V. has approximately 185 employees.
Merus N.V. has completed 11 funding rounds, raising a total of $1.04B. The latest funding stage is Post-IPO Equity.
Merus N.V. offers: Development of Cancer Treatments, Clinical Trials Management, Research and Development in Biotechnology, Multiclonics Therapeutics.
Top alternatives and competitors to Merus N.V. include OncoResponse, 2seventy bio, Antharis Therapeutics, Inc., Xilio Therapeutics, Inc., OncXerna Therapeutics . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Merus N.V. and OncoResponse are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Merus N.V., https://bouncewatch.com/company/merus-nv, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes